Home » Stocks » AFMD

Affimed N.V. (AFMD)

Stock Price: $5.22 USD 0.09 (1.75%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 599.18M
Revenue (ttm) 24.03M
Net Income (ttm) -36.37M
Shares Out 64.24M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $5.22
Previous Close $5.13
Change ($) 0.09
Change (%) 1.75%
Day's Open 5.20
Day's Range 4.78 - 5.29
Day's Volume 2,041,692
52-Week Range 1.42 - 7.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 3 weeks ago

Steven Cohen (Trades, Portfolio), the billionaire investor who leads Point72 Asset Management, disclosed earlier this week his firm upped its stake in Affimed NV (NASDAQ:AFMD) by 190.73%.

Benzinga - 1 month ago

Affimed N.V. (NASDAQ: AFMD) has entered into a clinical research collaboration with Roche Holding AG (OTC: RHHBF) to explore the combination of Affimed's AFM24 with Roche's atezolizumab (Tecen...

Other stocks mentioned: RHHBY
GlobeNewsWire - 1 month ago

Heidelberg, Germany, February 3, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced ...

GlobeNewsWire - 1 month ago

Heidelberg, Germany, January 15, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate abilit...

Zacks Investment Research - 1 month ago

Affimed (AFMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

Heidelberg, Germany, January 13, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate abilit...

GlobeNewsWire - 1 month ago

Heidelberg, Germany, January 12, 2021 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate abilit...

GlobeNewsWire - 1 month ago

Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno...

GlobeNewsWire - 1 month ago

Heidelberg, Germany, January 11, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno...

GlobeNewsWire - 2 months ago

Heidelberg, Germany, January 7, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today annou...

Seeking Alpha - 2 months ago

Affimed continues to amass a stockpile of partnerships and collaborations that amplifies the risk-reward profile for an AFMD investment. As a result, I am looking to accumulate a larger positi...

GlobeNewsWire - 3 months ago

Heidelberg, Germany, December 7, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno...

GlobeNewsWire - 3 months ago

 The phase 1b study showed a complete response (CR) rate of 46% (objective response rate [ORR] of 88%) at the recommended dose level in patients with relapsed/refractory (R/R) Hodgkin lymphoma...

Seeking Alpha - 3 months ago

Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 3 months ago

Affimed N.V.'s (AFMD) CEO Adi Hoess On Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 3 months ago

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 33.33% and 94.55%, respectively, for the quarter ended September 2020.

Benzinga - 3 months ago

Shares of Affimed (NASDAQ:AFMD) rose 11.3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), whi...

GlobeNewsWire - 3 months ago

Heidelberg, Germany, Novembe r 10 , 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today r...

GlobeNewsWire - 3 months ago

Affimed to grant license to AFM32 with options for additional ICE® molecules directed against targets not included in Affimed's current pipeline

GlobeNewsWire - 3 months ago

 Virtual data presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting on Wednesday, November 11, 2020

GlobeNewsWire - 4 months ago

 Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional targets

GlobeNewsWire - 4 months ago

Heidelberg, Germany, November 4, 2020 – Affimed N.V., (NASDAQ: AFMD) a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announce...

GlobeNewsWire - 4 months ago

Heidelberg, Germany, November 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno...

GlobeNewsWire - 4 months ago

Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced ...

GlobeNewsWire - 4 months ago

Heidelberg, Germany, and Santa Ana, California, October 20, 2020 – Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc., both clinical stage biotech companies focused on harnessing the power of ...

GlobeNewsWire - 4 months ago

Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today anno...

GlobeNewsWire - 5 months ago

Pilsen, Czech Republic, October 6, 2020 - AbCheck s.r.o., a leader in providing antibody drug discovery, engineering and optimization services to the biotech and pharmaceutical industry, today...

GlobeNewsWire - 5 months ago

Heidelberg, Germany, October 6, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today annou...

GlobeNewsWire - 5 months ago

Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today an...

GlobeNewsWire - 6 months ago

 Heidelberg, Germany, September 2, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today an...

Seeking Alpha - 6 months ago

Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -50.00% and -52.45%, respectively, for the quarter ended June 2020.

Benzinga - 6 months ago

Shares of Affimed (NASDAQ:AFMD) moved higher by 4% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 6 months ago

Heidelberg, Germany, August 11, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today repor...

GlobeNewsWire - 7 months ago

Heidelberg, Germany, August 5, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today annou...

GlobeNewsWire - 7 months ago

Heidelberg, Germany, August 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced to...

Zacks Investment Research - 7 months ago

Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 7 months ago

Unlike a lot of companies that are focused on the adaptive immune system, Affimed is developing a novel suite of products aimed at boosting innate immunity to fight cancer.

GlobeNewsWire - 7 months ago

Heidelberg, Germany, July 10, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced tod...

Seeking Alpha - 8 months ago

Affimed: Updates To Thesis, Time To Gain Exposure To Innate Immuno-Oncology

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor of Affimed

Zacks Investment Research - 8 months ago

Investors need to pay close attention to Affimed (AFMD) stock based on the movements in the options market lately.

Seeking Alpha - 8 months ago

Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

Shares of Affimed (NASDAQ:AFMD) decreased 3.0% in pre-market trading after the company reported Q1 results.

GlobeNewsWire - 8 months ago

             

GlobeNewsWire - 8 months ago

Heidelberg, Germany, June 22, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announ...

GlobeNewsWire - 8 months ago

 Heidelberg, Germany, June 17, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announ...

Zacks Investment Research - 8 months ago

Affimed (AFMD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

GlobeNewsWire - 8 months ago

  Mr. Smith brings broad financial management and US capital markets expertise

GlobeNewsWire - 9 months ago

REDIRECT is a Registration-directed Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30 positive Peripheral T-cell Ly...

About AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-bindi... [Read more...]

Industry
Biotechnology
IPO Date
Sep 12, 2014
CEO
Dr. Adi Hoess
Employees
137
Stock Exchange
NASDAQ
Ticker Symbol
AFMD
Full Company Profile

Financial Performance

In 2019, Affimed N.V.'s revenue was 21.39 million, a decrease of -9.88% compared to the previous year's 23.74 million. Losses were -32.37 million, 66.2% more than in 2018.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Affimed N.V. stock is "Strong Buy." The 12-month stock price forecast is 9.48, which is an increase of 81.61% from the latest price.

Price Target
$9.48
(81.61% upside)
Analyst Consensus: Strong Buy